MarketCapExport financials
DexCom (DXCM)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
DexCom Cash Flow 2025-2008 | DXCM
Brief cash flow overview of DexCom
The review uses the five latest available annual reports between 2021 and 2025.
Operating cash flow advanced from $442.5 million to $1.4 billion. A +225.6% gain and 34.3% CAGR show rapidly improving cash generation.
Core operations generated cash in every available annual observation. Stability was high.
Operating cash flow covered cumulative profit by 1.71x, providing strong cash confirmation.
Operating cash flow margin rose from 18.1% to 30.9%. The business generated more cash per unit of revenue.
Estimated working capital increased by $818.7 million, equal to 17.6% of latest revenue. More cash became tied up in receivables and inventory.
What the cash flows show
DexCom's cash position is positive. The business can fund investment and obligations mainly from internal sources.
Annual Cash Flow DexCom
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
1.44 B | 990 M | 748 M | 670 M | 442 M | 476 M | 314 M | 123 M | 92 M | 56.2 M | 49 M | 23.6 M | 2.4 M | -33.1 M | -30.1 M | -42.7 M | -39.4 M | - |
Depreciation & Amortization |
252 M | 218 M | 186 M | 156 M | 102 M | 67.1 M | 48.7 M | 29.1 M | 16.1 M | 15 M | 10.8 M | 8.4 M | 7 M | 6.6 M | 3.8 M | 2.4 M | 2.37 M | - |
Accounts Payables |
344 M | 345 M | 276 M | 238 M | 189 M | 163 M | 102 M | 75.5 M | 46.7 M | 24.5 M | 19 M | 9.9 M | 4.2 M | 3.9 M | 6.35 M | 5.35 M | - | - |
Accounts Receivables |
1.22 B | 1.01 B | 974 M | 713 M | 514 M | 428 M | 286 M | 227 M | 134 M | 102 M | 74.1 M | 42.4 M | 26.1 M | 19.5 M | 12.5 M | 6.67 M | - | - |
Total Inventories |
629 M | 543 M | 560 M | 307 M | 357 M | 235 M | 120 M | 70.7 M | 45.2 M | 45.4 M | 35.2 M | 16 M | 9 M | 7.4 M | 8.17 M | 8.11 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow DexCom
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
795 M | 526 M | - | 1.15 B | - | 184 M | - | - | - | 209 M | - | - | - | 155 M | - | 537 M | - | 71 M | - | 337 M | - | 27.8 M | - | 304 M | 156 M | 1.9 M | - | 171 M | 76.3 M | 11.8 M | - | 89.5 M | 32.7 M | -8.7 M | - | 50.8 M | 14.6 M | 300 K | - | 42.9 M | 19.9 M | -200 K | - | 37.7 M | 19.8 M | 3.4 M | - | 15.2 M | 3.8 M | -2.4 M | - | -2 M | -3.6 M | -4.5 M | - | -22.5 M | -16.5 M | -10.2 M | - | -18.6 M | -11.8 M | -9.29 M |
Depreciation & Amortization |
68.2 M | 67.1 M | - | 63.6 M | 63 M | 60 M | - | - | 52.1 M | 52.5 M | - | 1.7 M | 1.7 M | 41.6 M | - | 1.8 M | 1.9 M | 36.8 M | - | 69.9 M | - | 20.9 M | - | 46.7 M | 28.3 M | 13 M | - | 34.4 M | 21.5 M | 9.9 M | - | 20.5 M | 12.7 M | 6 M | 16.1 M | 11.9 M | 7.6 M | 3.7 M | - | 11.4 M | 7.3 M | 3.4 M | - | 7.7 M | 5 M | 2.4 M | - | 6 M | 3.8 M | 1.9 M | - | 5.1 M | 3.4 M | 1.8 M | - | 4.8 M | 2.7 M | 1.2 M | - | 2.7 M | 1.7 M | 806 K |
Accounts Payables |
424 M | 394 M | 344 M | 452 M | 472 M | 432 M | 345 M | 327 M | 307 M | 270 M | 276 M | 242 M | 269 M | 266 M | 238 M | 198 M | - | 150 M | 189 M | 210 M | 166 M | 152 M | 163 M | 163 M | 163 M | 163 M | 102 M | 102 M | 102 M | 102 M | 75.5 M | 75.5 M | 75.5 M | 75.5 M | 46.7 M | 46.7 M | 46.7 M | 46.7 M | 41.1 M | 24.5 M | 24.5 M | 24.5 M | 19 M | 19 M | 19 M | 19 M | 9.9 M | 9.9 M | 9.9 M | 9.9 M | 4.2 M | 4.2 M | 4.2 M | 4.2 M | 3.9 M | 3.9 M | 3.9 M | 7.98 M | 6.35 M | 2.81 M | 2.81 M | - |
Accounts Receivables |
1.26 B | 1.09 B | 1.22 B | 1.11 B | 1.35 B | 1.16 B | 1.01 B | 1 B | 945 M | 979 M | 974 M | 786 M | 751 M | 637 M | 713 M | 564 M | - | 544 M | 514 M | 529 M | 484 M | 443 M | 428 M | 428 M | 428 M | 428 M | 286 M | 286 M | 286 M | 286 M | 227 M | 227 M | 227 M | 227 M | 134 M | 134 M | 134 M | 134 M | 102 M | 102 M | 102 M | 102 M | 74.1 M | 74.1 M | 74.1 M | 74.1 M | 42.4 M | - | - | - | 26.1 M | - | - | - | 19.5 M | - | - | - | 12.5 M | - | - | - |
Total Inventories |
726 M | 694 M | 629 M | 604 M | 571 M | 538 M | 543 M | 586 M | 570 M | 589 M | 560 M | 499 M | 421 M | 366 M | 307 M | 311 M | - | 342 M | 357 M | 351 M | 319 M | 290 M | 235 M | 235 M | 235 M | 235 M | 120 M | 120 M | 120 M | 120 M | 70.7 M | 70.7 M | 70.7 M | 70.7 M | 45.2 M | 45.2 M | 45.2 M | 45.2 M | 45.4 M | 45.4 M | 45.4 M | 45.4 M | 35.2 M | 35.2 M | 35.2 M | 35.2 M | 16 M | 16 M | 16 M | 16 M | 9 M | 9 M | 9 M | 9 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 8.2 M | 8.17 M | 8.17 M | 8.17 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company DexCom, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Diagnostics research sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Organovo Holdings
ONVO
|
- | -2.3 % | $ 19.4 M |  USA |
 |
OpGen
OPGN
|
- | -16.95 % | $ 1.54 M | USA |
 |
PerkinElmer
PKI
|
- | -0.91 % | $ 14.7 B | USA |
 |
Soleno Therapeutics
SLNO
|
- | - | $ 2.69 B | USA |
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | USA |
 |
Biomerica
BMRA
|
$ 1.71 | -0.51 % | $ 4.98 M | USA |
 |
Myriad Genetics
MYGN
|
$ 5.57 | 0.54 % | $ 516 M | USA |
 |
Pacific Biosciences of California
PACB
|
$ 2.14 | 9.18 % | $ 642 M | USA |
 |
Neuronetics
STIM
|
$ 2.01 | 1.52 % | $ 133 M | USA |
 |
Agilent Technologies
A
|
$ 177.75 | 2.74 % | $ 50.5 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 344.87 | 9.31 % | $ 17.1 B | USA |
 |
Biodesix
BDSX
|
$ 23.93 | 0.25 % | $ 181 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 13.51 | 6.71 % | $ 142 M |  China |
 |
Bioventus
BVS
|
$ 14.24 | 2.08 % | $ 949 M | USA |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
CareDx, Inc
CDNA
|
$ 70.74 | 2.23 % | $ 3.77 B | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Co-Diagnostics
CODX
|
$ 0.64 | -0.82 % | $ 851 K | USA |
 |
Danaher Corporation
DHR
|
$ 233.86 | 4.32 % | $ 167 B | USA |
 |
Fulgent Genetics
FLGT
|
$ 20.13 | -0.98 % | $ 620 M | USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
IQVIA Holdings
IQV
|
$ 276.63 | 3.28 % | $ 47.6 B | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 323.75 | 0.19 % | $ 26.9 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 2.71 | 1.12 % | $ 88 K | USA |
 |
Lantheus Holdings
LNTH
|
$ 100.24 | -0.15 % | $ 6.77 B | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
Celcuity
CELC
|
$ 61.56 | 2.6 % | $ 2.88 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Medpace Holdings
MEDP
|
$ 662.48 | 6.43 % | $ 19.1 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 677.94 | 2.69 % | $ 34.6 B |  Schweiz |
 |
NeoGenomics
NEO
|
$ 17.04 | 2.53 % | $ 2.18 B | USA |
 |
Neogen Corporation
NEOG
|
$ 11.79 | 0.6 % | $ 2.56 B | USA |
 |
National Research Corporation
NRC
|
$ 20.31 | -1.84 % | $ 455 M | USA |
 |
Brainsway Ltd.
BWAY
|
$ 11.98 | -0.42 % | $ 407 M | Israel |
 |
Koninklijke Philips N.V.
PHG
|
$ 26.23 | 0.85 % | $ 24.9 B |  Niderland |
 |
Precipio
PRPO
|
$ 21.25 | -2.16 % | $ 34.1 M | USA |
 |
Castle Biosciences
CSTL
|
$ 34.37 | 3.68 % | $ 996 M | USA |
 |
Guardant Health
GH
|
$ 166.66 | 2.5 % | $ 20.9 B | USA |
 |
RadNet
RDNT
|
$ 68.41 | -1.78 % | $ 5.14 B | USA |
 |
DarioHealth Corp.
DRIO
|
$ 3.68 | -9.8 % | $ 14.7 M | Israel |